Pharmaceutical Business review

NeoStem raises $0.9 million in financing

The financing consists of units priced at $1.20 per unit with each unit consisting of one share of common stock and a warrant to purchase one share of common stock at $1.75 per share.

Robin Smith, CEO of NeoStem, said: “These funds will be instrumental in executing on our plan to educate potential clientele about our services, particularly in the Northeast which we believe will be a powerful market.”